DURECT Co. (DRRX) to Release Quarterly Earnings on Monday
DURECT Co. (NASDAQ:DRRX) will be announcing its earnings results after the market closes on Monday, October 30th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.
DURECT (NASDAQ:DRRX) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $4.32 million for the quarter, compared to analysts’ expectations of $5.17 million. DURECT had a negative return on equity of 5,651.82% and a negative net margin of 229.84%. On average, analysts expect DURECT to post $-0.2100 EPS for the current fiscal year and $-0.1600 EPS for the next fiscal year.
DURECT Co. (DRRX) traded up 9.7608% during trading on Monday, reaching $0.8535. The company’s stock had a trading volume of 1,288,628 shares. DURECT Co. has a 52 week low of $0.74 and a 52 week high of $2.17. The firm has a 50-day moving average price of $1.76 and a 200-day moving average price of $1.46. The firm’s market capitalization is $125.46 million.
A hedge fund recently raised its stake in DURECT stock. The Manufacturers Life Insurance Company boosted its holdings in shares of DURECT Co. (NASDAQ:DRRX) by 12.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 120,977 shares of the specialty pharmaceutical company’s stock after buying an additional 13,072 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.08% of DURECT worth $189,000 at the end of the most recent quarter. 45.82% of the stock is owned by institutional investors.
A number of analysts have recently issued reports on the company. Laidlaw reduced their target price on DURECT from $3.00 to $2.00 and set a “buy” rating for the company in a report on Friday. Stifel Nicolaus upgraded DURECT from a “hold” rating to a “buy” rating and increased their target price for the company from $1.25 to $3.00 in a report on Wednesday, July 12th. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of DURECT in a report on Sunday, June 25th. Finally, ValuEngine upgraded DURECT from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th.
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Co. and related companies with MarketBeat.com's FREE daily email newsletter.